XCath, a medical device startup partially owned by Crescent Enterprises, closed a USD 30 mn Series C financing round, lifting its total funding to USD 92 mn, according to a press release. Crescent Enterprises and Fred Moll, chairman of XCath’s board, co-led the investment.

The capital will be used to advance XCath’s Iris robotic system and to develop remote-assisted mechanical thrombectomy procedures, aiming to improve treatment for stroke and other neurovascular conditions.

About the company: Founded in 2017, XCath is developing the world’s first commercially practical endovascular surgical robot. Operating out of Houston, Texas, and Pangyo, South Korea, the company focuses on treating life-threatening conditions like stroke and brain aneurysms.

Tags: